Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Hypertriglyceridemia Clinical Trials

12 recruiting trials for Hypertriglyceridemia. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
12
Total Trials
12
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT06564584

Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with...

Sponsor: OrsoBio, IncEnrolling: 304 locations
RECRUITINGNCT05743868

Metabolic Heterogeneity Underlying Hypertriglyceridemia: Hepatic Triglyceride Biosynthesis in Humans With Different...

The focus of this cross-sectional study is to determine the effects of tissue-specific (adipose tissue or muscle) vs global (combined) insulin resistance (IR) on hepatic...

Sponsor: Yale UniversityEnrolling: 401 location
RECRUITINGNCT06206759

Vitamin C Administration and Triglycerides Level in Critical Care Patients

Vitamin C (ascorbic acid) is a water-soluble vitamin with antioxidant properties. Previous studies showed that the administration of vitamin C was associated with decreased...

Sponsor: Meir Medical CenterEnrolling: 20001 location
RECRUITINGPhase 3NCT06822790

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required...

Sponsor: Arrowhead PharmaceuticalsEnrolling: 86920 locations
RECRUITINGPhase 2 / Phase 3NCT06220266

Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women

The goal of this clinical trial is to learn about the effects of phytoestrogen from Pueraria Mirifica in improvement of serum lipid parameters. The primary question it aims to...

Sponsor: Dhurakij Pundit UniversityEnrolling: 101 location
RECRUITINGNCT07200674

Interest of High-speed Centrifugation for Measuring Anti-Xa Activity on Lipemic Plasma

Some hemostasis techniques require spectrophotometric measurements. These are then subject to interference from the sample's lipemia (postprandial, hypertriglyceridemia, etc.),...

Sponsor: University Hospital, Strasbourg, FranceEnrolling: 1501 location
RECRUITINGPhase 1NCT07491172

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available...

Sponsor: CRISPR Therapeutics AGEnrolling: 9018 locations
RECRUITINGEarly Phase 1NCT06494488

Differential Thrombogenesis by EPA and DHA Mediated by HDL

The goal of this study is to learn more about omega-3 polyunsaturated fatty acids supplementation on blood lipid profile and platelets in patients with high cholesterol levels....

Sponsor: The Miriam HospitalEnrolling: 801 location
RECRUITINGPhase 1NCT06451770

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201...

Sponsor: Verve Therapeutics, Inc.Enrolling: 3610 locations
RECRUITINGNCT07508930

Russian Extreme Hypertriglyceridemia Registry

The REGGI registry is a prospective, multicenter observational registry in Russia designed to collect data on patients with extreme hypertriglyceridemia (triglyceride levels ≥10...

Sponsor: Russian Cardiology Research and Production CenterEnrolling: 5006 locations
RECRUITINGNCT07004777

Effect of Consuming n-3 Polyunsaturated Fatty Acids Rich Foods on Triglyceride Concentration and Lipoprotein Composition

Hypertriglyceridemia is one of the most prevalent lipid profile disorders and is linked to a large proportion of mortality in Mexico and around the world. Various international...

Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranEnrolling: 3751 location
RECRUITINGNCT07406191

WB-EMS Effects on Cardiometabolic Risk Factors

From the age of 50 onwards, there is a disproportionate decline in muscle strength, mass and function, which can be prevented or at least delayed by physical training....

Sponsor: University of Erlangen-Nürnberg Medical SchoolEnrolling: 422 locations

Frequently Asked Questions

There are currently 12 clinical trials for Hypertriglyceridemia, with 12 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Hypertriglyceridemia, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Hypertriglyceridemia, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

this entity is one of the data points covered by this site’s U.S. clinical trials and research registries dataset. The detail above comes directly from the NIH ClinicalTrials.gov registry; the context that follows situates the headline numbers against the broader distribution across active and historical clinical trials.

Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.